Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVOLUTION
2024-516844-25-01Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of valproic acid in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: authorised.
02
Drugs
valproic acid
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-516844-25-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516844-25-01.